| HOME >> BIOLOGY >> TECHNOLOGY |
SAN DIEGO, Aug. 20 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced the enhancement of its management team with the appointment of Andrew R. de Guttadauro as Vice President, Corporate Development.
Prior to joining Vical, Mr. de Guttadauro was Senior Director of Strategy at Biogen Idec since February 2007, following a two-year assignment overseeing the commercial development of that company's Zevalin, the first radioimmunotherapy product approved for use in the United States. Before joining Biogen Idec, he spent the prior year at MedImmune, where he directed marketing efforts for the FluMist inhaled influenza vaccine. Mr. de Guttadauro served in various marketing positions of increasing responsibility at Amgen Inc. over a six-year period, with direct involvement in the marketing of Enbrel, Kineret, Aranesp, and Epogen products. He spent the first seven years of his career at Tap Pharmaceuticals, where he served in a series of sales and marketing positions, including contributions to the success of Prevacid and Lupron. Mr. de Guttadauro earned a bachelor of science degree in engineering from the United States Military Academy at West Point, followed by a three-year tour of duty as a Captain in the U.S. Army.
Vijay B. Samant, Vical's President and Chief Executive Officer, said,
"We are very pleased to welcome Andrew to Vical's management team at this
exciting time in the company's development. His proven leadership
capabilities, solid project management skills, and breadth of experience in
product sales and marketing, add another dimension to our current
capabilities. As we advance with our independent product development
programs, we look forward to applying Andrew's expertise in p
'/>"/>
SOURCE Vical Incorporated![]() Copyright©2007 PR Newswire. |